Enterprise Value

9.50B

Cash

1.169B

Avg Qtr Burn

N/A

Short % of Float

0.00%

Insider Ownership

0.00%

Institutional Own.

0.01%

Qtr Updated

12/31/22


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Tazverik (Tazemetostat ) Details
NHL (Non-Hodgkins Lymphoma), R/R FL (Relapsed or Refractory Follicular Lymphoma) and ES (Epithelioid Sarcoma)

Approved

Quarterly sales

Bylvay (Odevixibat) (ileal bile acid transport inhibitor) Details
Progressive familial intrahepatic cholestasis

Approved

Quarterly sales

Palovarotene Details
Genetic disorder, Fibrodysplasia ossificans progressiva, Rare genetic disease

PDUFA

Approval decision

PDUFA

Approval decision

Palovarotene Details
Genetic disorder, Fibrodysplasia ossificans progressiva, Rare genetic disease

PDUFA

Adcomm

Tazemetostat + rituximab + lenalidomide Details
R/R FL (Relapsed or Refractory Follicular Lymphoma)

Phase 3

Data readout

Onivyde Details
Cancer, Pancreatic cancer, Carcinoma

Phase 3

Data readout

Cabometyx Details
Cancer, Non-small cell lung carcinoma

Phase 3

Data readout

Odevixibat (ileal bile acid transport inhibitor) Details
Biliary atresia, Liver disease, COVID-19

Phase 3

Data readout

Tazemetostat + R-CHOP Details
Follicular lymphoma, Diffuse large B cell lymphoma

Phase 2

Interim update

Tazemetostat + Enzalutamide Details
Cancer, Prostate cancer, Castration-resistant prostate cancer

Phase 2

Interim update

Tazemetostat + Mosunetuzumab Details
Cancer, Follicular lymphoma

Phase 1/2

Interim update